Atricure Inc. Stock
Atricure Inc. Stock
A loss of -1.650% shows a downward development for Atricure Inc..
Atricure Inc. is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a target price of 43 € there is a hugely positive potential of 80.67% for Atricure Inc. compared to the current price of 23.8 €.
Pros and Cons of Atricure Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | -1.650% | -4.032% | -7.752% | -61.613% | -30.000% | -61.613% | -57.117% |
| SI-BONE Inc | -1.790% | 0.000% | -17.910% | -16.667% | -34.911% | - | - |
| Lantheus Holdings Inc | -0.550% | -0.362% | 1.134% | -26.481% | 15.420% | -13.699% | - |
| Orasure Tech | -0.760% | -0.763% | 4.000% | -15.033% | 26.214% | -50.943% | -73.615% |
Comments
AtriCure (NASDAQ:ATRC) was given a new $55.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (NASDAQ:ATRC) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $54.00 price target on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (NASDAQ:ATRC) had its price target raised by analysts at JPMorgan Chase & Co. from $42.00 to $48.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
News
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
This medical device innovator for cardiac surgery reported an insider sale amid a year of negative total returns.
Doraiswamy Vinayak, Chief Scientific Officer of AtriCure (NASDAQ:ATRC), reported the
Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?
Sven Wehrwein, a member of the Board of Directors at AtriCure (NASDAQ:ATRC), exercised 10,000 non-qualified stock options and immediately sold the underlying shares in derivative transactions on